Unidad de Cáncer Ginecológico, Genitourinario y de piel

Unidad de Cáncer Ginecológico, Genitourinanrio y de piel


Unidad de Cáncer Genitourinario




 

  • A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects who have Relapsed After, or are Refractory to Standard Therapy.

 

  • OPEN LABEL 1b/2 STUDY OF  A NOVEL FGFR3 INHIBITOR (B701) COMBINED WITH PEMBRO IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO HAVE PROGRESSED FOLLOWING PLATINUM BASED CHEMOTHERAPY.

     
  • Estudio de fase III, multicéntrico, multinacional, aleatorizado, abierto, con grupos paralelos sobre avelumab* (MSB0010718C) más los mejores cuidados paliativos frente a los mejores cuidados paliativos solo como tratamiento de mantenimiento en pacientes con cáncer urotelial localmente avanzado o metastásico sin progresión de la enfermedad tras completar la quimioterapia de primera línea basada en platino.

     
  • A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL COOMMPARING CB-839 IN CONBINATION WITH CABOZANTINIB (CB-CABO)VS. PLACEBO WITH CABOZANTINIB (PBO-CABO) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA (RCC)

     
  • Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with genetic alterations in ERBB receptors.

     
  • Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cáncer.

 

 

 


To Top